Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | PAK4 | O96013 | 3/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CX3CR1 | P49238 | 2/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13657244 | 0.87 | RAB9A (0.39) | RAB9ASMN1; SMN2NPC1HSP90AA1CXCR2 | |
| SCHEMBL14287459 | 0.85 | RAB9A (0.42) | RAB9ASMN1; SMN2NPC1HSP90AA1CXCR2 | |
| SCHEMBL13650603 | 0.77 | RAB9A (0.43) | RAB9ASMN1; SMN2NPC1HSP90AA1METAP2 | |
| SCHEMBL4108740 | 0.75 | CTSB (0.36) | RAB9ASMN1; SMN2NPC1HSP90AA1METAP2 | |
| SCHEMBL14287456 | 0.71 | RAB9A (0.42) | RAB9ASMN1; SMN2NPC1HSP90AA1CXCR2 | |
| SCHEMBL13752162 | 0.63 | RAB9A (0.70) | RAB9ASMN1; SMN2NPC1HSP90AA1CXCR2 | |
| SCHEMBL13650599 | 0.63 | RAB9A (0.43) | RAB9ASMN1; SMN2NPC1HSP90AA1METAP2 | |
| SCHEMBL13894902 | 0.62 | CTSB (0.36) | RAB9ASMN1; SMN2NPC1HSP90AA1ALOX15 | |
| SCHEMBL4125812 | 0.62 | ALDH1A1 (0.39) | RAB9ASMN1; SMN2NPC1HSP90AA1PAK4 | |
| SCHEMBL490098 | 0.61 | RAB9A (0.62) | RAB9ASMN1; SMN2NPC1HSP90AA1CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247501-A1 | PROTEIN KINASE INHIBITORS | POLARIS GROUP (TW) | 2009-10-01 | — | — | US | disclosed |
| US-7517882-B2 | Protein kinase inhibitors | POLARIS GROUP (CN) | 2009-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247501-A1 | PROTEIN KINASE INHIBITORS | MAP3K15, MAP3K20, MAP3K5 | RAB9A 2131/4885SMN1; SMN2 1861/4885NPC1 3693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.